Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions†

Fabio Doro,*a Cinzia Colombo,a Chiara Alberti,b Daniela Arosio,c Laura Belvisi,a,c Cesare Casagrande,b Roberto Fanelli,d Leonardo Manzoni,c Emilio Parisini,e Umberto Piarulli,d Elena Luison,b Mariangela Figini,b Antonella Tomassetti*b and Monica Civera**a

We report a first set of peptidomimetic ligands mimicking the adhesive interface identified by recent crystallographic structures of E- and N-cadherin. Compounds 2 and 3 inhibit adhesion of epithelial ovarian cancer (EOC) cells with improved efficacy compared to the ADH-1 peptide, a N-cadherin antagonist that is in early clinical trials in EOC patients.

Cadherins are a large family of calcium-dependent cell adhesion molecules that are mostly expressed at the intercellular junctions. They are known to play a key role in important physiological processes such as tissue morphogenesis and stability, as well as in the immune system regulation. Over the past 20 years, dysregulation of the type I epithelial E-cadherin (cadh) and neuronal N-cadh has been shown to correlate with tumor progression and other pathological processes.1 The switch in expression from E-cadh to N-cadh is an important indicator of the epithelial–mesenchymal transition (EMT) occurring during cancer progression.1 Although E-cadh is considered a repressor for the majority of carcinomas, in epithelial ovarian cancer (EOC) E-cadh persists during tumor progression.2 We have shown that E- and N-cadh can be co-expressed in some advanced-stage EOCs and that E-cadh expression and homophilic interaction contribute to the proliferation of EOC cells.2

Cadherins from opposing cells interact by means of their extracellular regions, constituted by five Ig-like domains (EC1–EC5), and form multiple trans homophilic dimers arranged in a zipper-like fashion across the cellular adherens junctions.3,4 Several X-ray structures of type I and II cadherin ectodomains5 have shown that trans dimerization occurs through the opening of the highly conserved N-terminal six-residue portion of the EC1 (the “adhesion arm”) that contains a Trp residue in position 2 (Trp2), and its swapping into an acceptor pocket of the EC1 of the interacting protein, thus resulting in the so-called “strand dimer” formation. However, the complex and highly dynamical cadherin dimerization pathway has only been partially elucidated by the wealth of biochemical and biophysical studies performed to date.4 Ultimately, a variety of transient yet critical key intermolecular interactions involving different residues at different stages of the full cadherin dimerization trajectory play all a critical role in guiding the system through a number of intermediate intermolecular protein–protein arrangements during the recognition process that leads from monomeric cadherin to strand-dimer-formation and back.6

As a result of this highly dynamic behaviour and despite a growing interest in the field, the rational design of small ligands targeting cadherin protein–protein interactions is still in a very early stage. The first crystal structure of the N-cadh EC1 dimer revealed an association interface characterized by the His79-Ala80-Val81 (HAV) and the Ile53-Asn54-Pro55 (INP) sequences and not involving the strand swapping portion of the molecule.7 This triggered an interest in the synthesis of libraries of cyclic peptides based on HAV or INP sequences and of non-peptide HAV mimics for the inhibition of the cadherin dimerization process.8 Among them, the antagonist peptide N-Ac-CHAVC-NH2 (ADH-1 or Exherin™, Fig. 1) containing the HAV motif was promoted to phase I clinical trials in patients with advanced solid tumors which express N-cadh.9

In this paper, we report the first small library of peptidomimetics based on the tetrapeptide sequence Asp1-Trp2-Val3-Ile4 (DWV) of the N- and E-cadh N-terminal “adhesive arm”. To the best of our knowledge, this work represents the first attempt to rationally design small molecules targeting the strand dimer interfaces identified by recent crystallographic
structures. Our compounds were tested in biochemical and functional assays on EOC cells for their ability to inhibit both N- and E-cadh homophilic interactions relative to ADH-1.

About 30 peptidomimetics of general formula NH$_3^+$-Asp-$\text{scff}$old-Ile-NHCH$_3$ were built in silico by replacing the central dipeptide Trp$_2$-Val$_3$ unit of the DWVI adhesive motif with several scffolds developed in our and other laboratories (Fig. 2). All the peptidomimetics featured a conformationally constrained scffold bearing a benzyl or phenyl ring to mimic the indole moiety of Trp$_2$ in the native sequence. Based on the molecular architecture of the scffolds, the aromatic ring was expected to be differently oriented into the binding pocket. To evaluate the ability of each of the compounds of our virtual library to reproduce the DWVI key interactions observed in the X-ray dimer structures (Fig. S1†) and during molecular dynamics simulations (Fig. S2 and S3†), we built a model of the EC1 fragment of E- and N-cadh starting from the corresponding X-ray structures and set up a docking protocol using the Glide V5.7 software (see ESI†).

Docking results were sorted according to the Glide score and filtered to match the two most important binding interactions: (i) the formation of an intermolecular salt bridge between the charged N-terminal amino group of Asp$_1$ and the side chain carboxylate of Glu$_{89}$ and (ii) the anchoring of the Trp$_2$ side chain into a hydrophobic pocket described for the DWVI motif. Based on this analysis, three ligands were selected for synthesis and biological assays (Fig. 1).

In the docking poses, all the three ligands form the salt bridge (i) and insert the scaffold benzyl ring into the corresponding hydrophobic pocket of Trp$_2$ (ii). In addition, in the N-cadh binding site an electrostatic interaction between ligand Asp$_1$-NH$_3^+$ and the side chain of Asp$_{27}$ is also observed, while in E-cadh there is the formation of a hydrogen bond with Asn$_{27}$. The main difference in the binding mode of the three ligands is related to their 3D alignment with respect to the DWVI sequence of the crystallographic structures: while 2 and 3 are able to mimic the extended backbone arrangement of the reference tetrapeptide in both cadherin receptors (see Fig. 3 and S4† for docking results of 3), 1 orients the Ile residue back to the Asp$_1$ amino acid and does not reproduce the experimental backbone conformation (Fig. S5†).

The three ligands were successfully synthesized using conventional high-yielding synthetic pathways in solution and in the solid phase (see ESI†).

The compounds were tested by ELISA for their ability to inhibit calcium-dependent cadherin binding using the N-cadh-expressing EOC cell line SKOV3 and N-cadh-Fc chimeric protein. Ligands 2 and 3 at 2 mM concentration inhibited N-cadh homophilic binding by 78% and 84%, respectively, and 50% and 65% at 1 mM concentration (Fig. 4A). Conversely, at 2 mM concentration ADH-1 and 1 provided about 50% inhibition of N-cadh-Fc/cells interactions and appeared nearly ineffective at 1 mM concentration (Fig. 4A). The compounds were then evaluated for their ability to inhibit EOC cells adhesion by observing the formation of cell monolayers in the presence of each ligand at 2 different concentrations (2 and 1 mM). As with ADH-1, at 2 mM concentration all compounds were able to inhibit the formation of cell mono-
layers of N-cadh-expressing cells (Fig. S6†). Notably, 2 and 3 were also active at 1 mM concentration, and 3 was able to inhibit cell–cell aggregation of N-cadh-expressing cells in suspension (Fig. 4B). When tested on the E-cadh-expressing EOC cell line OAW42, all compounds were found to be less efficient in inhibiting both E-cadh homophilic interactions and the formation of cell monolayers, with significant effects observed only at 2 mM concentration (Fig. S6 and S7†). In particular, by ELISA, at the concentration of 2 mM 1 and 3 gave about 50% inhibition of E-cadh-Fc binding to the cells while ADH-1 showed 30% inhibition (Fig. S7†), indicating a slightly better efficacy compared to ADH-1 in inhibiting also E-cadh homophilic interactions. Compound 2 was also able to inhibit the formation of cell monolayers at 1 mM concentration (Fig. S6†).

Overall, compounds 2 and 3 resulted to be effective in inhibiting N-cadh homophilic and, to some extent, also E-cadh homophilic adhesion. Encouraged by the very promising results with N-cadh-expressing cells, we set out to evaluate by surface plasmon resonance (SPR) analysis the ability of the two compounds to specifically inhibit the N-cadh homo-dimerization in a cell-free experiment using the N-cadh-Fc recombinant protein. At 10 μM concentrations compounds 2 and 3 provided 98% and 55% inhibition of N-cadh homophilic binding, respectively, while ADH-1 showed only 28% inhibition (Fig. S8†). These data demonstrate the ability of both compounds 2 and 3 to specifically bind to N-cadh even in the μM range.

The combination of our computational investigation with the results of SPR assays has started to shed light on the ligand structural requirements for binding to N-cadh. For instance, it appears that the best inhibitors (2 and 3) of N-cadh homophilic binding maintain the key (i) and (ii) interactions and also align with the DWVI backbone (Fig. 3). Although N- and E-cadh share similar adhesive binding features for the DWVI sequence† and no significant differences were observed in the interaction mode of our peptidomimetic ligands in the two cadherin docking models, the tests on the E-cadh-expressing EOC cell line OAW42 showed lower inhibition capability of E-cadh homophilic binding compared with those of N-cadh. Since a detailed picture of the complete adhesion pathway in the different cadherin family members is still elusive† and a variety of factors can contribute to the formation and dissociation of cadherin dimers on cell membranes, our results can be interpreted in light of different considerations. First, two-dimensional affinities measured by micropipette adhesion assays on cell lines expressing E- or N-cadhs, have shown that E-cadh homophilic binding is stronger than that of N-cadh. For this reason, our compounds might be less efficient in inhibiting E-cadh than N-cadh interactions. Moreover, based on compelling structural data,†,5 we decided to focus exclusively on the inhibition of the swapped-dimer formation targeting the EC1 domain, although several extracellular domains are known to be involved in the formation of highly dynamic and transient protein–protein contacts at the adhesive interface.

It is worth stressing that targeting the interfaces between proteins has huge therapeutic potential, but it still remains a challenge to discover small drug-like molecules that are capable of modulating those protein–protein interactions that are by their nature highly dynamical. In fact, it is clear that the dynamic features of the cadherin dimerization process are likely to play against a traditional drug design approach. Accordingly, the design of a stable molecular interactor against the adhesion pocket would not just prove difficult but it would fail to achieve complete inhibition. However, peptidomimetic molecules that can transiently interfere with structurally validated intermediates in the cadherin dimerization pathway may successfully modulate cadherin-mediated adhesion, even in the absence of an unequivocal identification of the actual binding site and mode.

**Conclusions**

In this work, we report a first set of peptidomimetic ligands mimicking the adhesive E- and N-cadh DWVI sequence. Remarkably, two of our peptidomimetics inhibit the N-cadherin-mediated adhesion process in EOC cells with somewhat improved efficacy compared to the ADH-1 cyclic peptide, which is being investigated in phase I clinical trials as a N-cadherin antagonist in various tumors, including EOCs.9
Thus, the small molecules generated in the present study are likely to represent new leads for the development of a novel class of modulators of cadherin-mediated adhesion. Such compounds may play an important role in the investigation of cellular processes, and in the design of novel diagnostic and therapeutic approaches against tumors, especially EOCs. Indeed, since the majority of EOCs grow and disseminate in the peritoneal cavity, the locoregional administration of drugs would allow the use of cadherin inhibitors without interfering with the cadherins expressed in normal epithelia.

Acknowledgements

We thank Università degli Studi di Milano for PhD Fellowship to FD and CINECA for computing facilities. We also gratefully acknowledge Ministero dell’Università e della Ricerca for financial support to MC (RBFR088ITV project), the AIRC for financial support to AT and the European Union for the FP7-PEOPLE-2010-RG grant to EP (DETACH – N.268231). We thank Dr Silvana Canevari for the useful suggestions and support.

Notes and references

1 G. Berx and F. van Roy, *Cold Spring Harbor Perspect. Biol.*, 2009, 1, a003129; O. W. Blaschuk and E. Devenyi, *Eur. J. Pharmacol*, 2009, 625, 195.

2 G. De Santis, S. Miotti, M. Mazzi, S. Canevari and A. Tomassetti, *Oncogene*, 2009, 28, 1206.

3 J. Brach, O. J. Harrison, B. Honig and L. Shapiro, *Trends Cell Biol.*, 2012, 22, 299.

4 D. Leckband and S. Sivasankar, *Curr. Opin. Cell Biol.*, 2012, 24, 620; J. Vendome, S. Posy, X. Jin, F. Bahna, G. Ahlsen, L. Shapiro and B. Honig, *Nat. Struct. Mol. Biol.*, 2011, 18, 693.

5 O. J. Harrison, X. Jin, S. Hong, F. Bahna, G. Ahlsen, J. Brach, Y. Wu, J. Vendome, K. Felsovalyi, C. M. Hampton, R. B. Troyanovsky, A. Ben-Shaul, J. Frank, S. M. Troyanovsky, L. Shapiro and B. Honig, *Structure*, 2011, 19, 244; E. Parisini, J. M. G. Higgins, J. Liu, M. B. Brenner and J. Wang, *J. Mol. Biol.*, 2007, 373, 401; T. J. Boggon, J. Murray, S. Chappuis-Flament, E. Wong, B. M. Gumbiner and L. Shapiro, *Science*, 2002, 296, 1308; S. D. Patel, C. Ciatto, C. P. Chen, F. Bahna, M. Rajebhosale, N. Arkus, I. Schieren, T. M. Jessell, B. Honig, S. R. Price and L. Shapiro, *Cell*, 2006, 124, 1255.

6 Y. Li, N. L. Altorelli, F. Bahna, B. Honig, L. Shapiro and A. G. Palmer 3rd, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, 110, 16462.

7 L. Shapiro, A. M. Fannon, P. D. Kwong, A. Thompson, M. S. Lehmann, G. Grüb, J. F. Legrand, J. Als-Nielsen, D. R. Colman and W. A. Hendrickson, *Nature*, 1995, 374, 327.

8 E. Williams, G. Williams, B. J. Gour, O. W. Blaschuk and P. Doherty, *J. Biol. Chem.*, 2000, 275, 4007; G. Williams, E.-J. Williams and P. Doherty, *J. Biol. Chem.*, 2002, 277, 4361; S. M. Burden-Gulley, T. J. Gates, S. E. L. Craig, S. F. Bou, S. A. Olander, S. Howell, M. Gupta and S. M. Brady-Kalnay, *Peptides*, 2009, 30, 2380.

9 O. W. Blaschuk, *Cell Tissue Res.*, 2012, 348, 309; A. Perotti, C. Sessa, A. Mancuso, C. Nofrasco, S. Cresta, A. Locatelli, M. L. Careggi, K. Passera, A. Braghetto, D. Scaramuzza, F. Zanaboni, A. Fasolo, G. Capri, M. Miani, W. P. Peters and L. Gianni, *Ann. Oncol.*, 2009, 20, 741; N. Varom, D. Stewart, R. Malik, J. Wells, L. Avruch and D. J. Jonker, *Curr. Clin. Pharmacol.*, 2013, 8, 81.

10 L. Manzoni, D. Arosio, L. Belvisi, A. Bracci, M. Colombo, D. Invernizzi and C. Scolastico, *J. Org. Chem.*, 2005, 70, 4124; A. S. M. Ressurreição, A. Bordessa, M. Civera, L. Belvisi, C. Gennari and U. Piarulli, *J. Org. Chem.*, 2008, 73, 652; D. Arosio, L. Belvisi, L. Colombo, M. Colombo, D. Invernizzi, L. Manzoni, D. Potenza, M. Serra, M. Castorina, C. Pisano and C. Scolastico, *ChemMedChem*, 2008, 3, 1589; L. Manzoni, L. Belvisi, D. Arosio, M. Civera, M. Pilkington-Miska, D. Potenza, A. Caprini, E. M. V. Araldi, E. Monferini, M. Mancino, F. Podestà and C. Scolastico, *ChemMedChem*, 2009, 4, 615; M. Marchini, M. Mingozzi, R. Colombo, I. Guzzetti, L. Belvisi, F. Vasile, D. Potenza, U. Piarulli, D. Arosio and C. Gennari, *Chem. – Eur. J.*, 2012, 18, 6195.

11 Y. Peng, H. Sun and S. Wang, *Tetrahedron Lett.*, 2006, 47, 4769; L. M. Beal, B. Liu, W. Chu and K. D. Moeller, *Tetrahedron*, 2000, 56, 10113.

12 *Glide, version 5.7*, Schrödinger, LLC, New York, 2011.

13 P. Thiery, W. Engl, V. Viasnoff and S. Dufour, *Curr. Opin. Cell Biol.*, 2012, 24, 614.